Ultragenyx Pharma (RARE) Tops Q2 EPS by 14c; offers guidance

Ultragenyx Pharma (NASDAQ: RARE) reported Q2 EPS of ($1.52), $0.14 better than the analyst estimate of ($1.66). Revenue for the quarter came in at $147.02 million versus the consensus estimate of $123.2 million.

GUIDANCE:

Ultragenyx Pharma sees FY2024 revenue of $530-550 million, versus the consensus of $512 million.

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

You May Also Be Interested In

• Casey's General Stores (CASY) Tops Q1 EPS by 69c
• ServiceTitan, Inc. (TTAN) Misses Q2 EPS by 1c, Offers Guidance
• BMO Capital Starts Abercrombie & Fitch (anf) at Outperform